Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16015507 | 1.00 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL15338277 | 0.82 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL13458474 | 0.81 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL1711198 | 0.80 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL1711202 | 0.80 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL14213008 | 0.80 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL2693885 | 0.78 | GPR119 (0.33) | MEN1KMT2A | |
| SCHEMBL4133054 | 0.78 | GPR119 (0.33) | MEN1KMT2A | |
| SCHEMBL14213014 | 0.72 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL13455534 | 0.72 | MEN1 (0.32) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-20140079693-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079693-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MEN1 2942/4885KMT2A 655/4885 |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MEN1 2942/4885KMT2A 655/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | MEN1 2942/4885KMT2A 655/4885 |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MEN1 2942/4885KMT2A 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.